Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease

Published:2013-07-01 Issue:6 Volume:4 Page:517-524
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Invest

Author:

Chang Eugene¹,Park Cheol-Young²,Park Sung Woo²

Affiliation:

1. Diabetes Research Institute; Kangbuk Samsung Hospital; Sungkyunkwan University School of Medicine; Seoul Korea

2. Division of Endocrinology and Metabolism; Department of Internal Medicine; Kangbuk Samsung Hospital; Sungkyunkwan University School of Medicine; Seoul Korea

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12107/fullpdf

Reference92 articles.

1. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease;Caldwell;Hepatology,1999

2. Nonalcoholic fatty liver disease;Angulo;N Engl J Med,2002

3. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity;Browning;Hepatology,2004

4. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures;Zelber-Sagi;Liver Int,2006

5. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?;Amarapurkar;J Gastroenterol Hepatol,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study;World Journal of Diabetes;2024-05-15

2. Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD;PLOS ONE;2024-04-17

3. Clinical improvement of some indicators of the activity of non-alcoholic fatty liver disease after correction of intestinal dysbiosis with dietary fiber;Experimental and Clinical Gastroenterology;2024-03-26

4. Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation;Frigid Zone Medicine;2024-03-01

5. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin;Diabetes, Obesity and Metabolism;2024-02-29